Search

Your search keyword '"Kanz L"' showing total 1,481 results
Start Over Author "Kanz L"
1,481 results on '"Kanz L"'

4. Hämostyptika

Author

Koscielny, J., Jámbor, C., Weber, C. F., Hellstern, P., von Heymann, C., Greinacher, A., Kopp, H.-G., Möhle, R., Kanz, L., Pötzsch, Bernd, editor, and Madlener, Katharina, editor

Published
2010
Full Text
View/download PDF

6. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author

Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, and Hasford, J

Published
2017
Full Text
View/download PDF

12. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Author

Hanfstein, B, Shlyakhto, V, Lauseker, M, Hehlmann, R, Saussele, S, Dietz, C, Erben, P, Fabarius, A, Proetel, U, Schnittger, S, Krause, S W, Schubert, J, Einsele, H, Hänel, M, Dengler, J, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Hofmann, W-K, Hochhaus, A, and Müller, M C

Published
2014
Full Text
View/download PDF

13. Ex Vivo Manipulation of Peripheral Blood CD34+ Cells

Author

Brugger, W., Scheding, S., Bühring, H.-J., Vogel, W., Ziegler, B., Brossart, P., Stuhler, G., Kanz, L., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

24. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

Author

Henes, J., Oliveira, M.C., Labopin, M., Badoglio, M., Scherer, H.U., Papa, N. del, Daikeler, T., Schmalzing, M., Schroers, R., Martin, T., Pugnet, G., Simoes, B., Michonneau, D., Marijt, E.W.A., Lioure, B., Bay, J.O., Snowden, J.A., Rovira, M., Huynh, A., Onida, F., Kanz, L., Marjanovic, Z., Farge, D., NISSC1 Members, University of São Paulo (USP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre International des greffes [CHU Saint-Antoine] (EBMT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Leiden University Medical Center (LUMC), University of Basel (Unibas), CHU Strasbourg, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

Subjects
Adult, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Aucun, Hematopoietic stem cell transplantation, Transplantation, Autologous, MESH: Scleroderma, Systemic, Article, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Bone Marrow, MESH: Autoimmune Diseases, Internal medicine, Clinical endpoint, Humans, Medicine, Prospective Studies, Progression-free survival, MESH: Hematopoietic Stem Cell Transplantation, MESH: Transplantation Conditioning, Aged, MESH: Aged, 030203 arthritis & rheumatology, MESH: Humans, Scleroderma, Systemic, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, MESH: Cyclophosphamide, MESH: Adult, Hematology, TRANSPLANTE AUTÓLOGO, MESH: Transplantation, Autologous, MESH: Prospective Studies, 3. Good health, Transplantation, MESH: Scleroderma, Diffuse, 030220 oncology & carcinogenesis, Scleroderma, Diffuse, MESH: Bone Marrow, Stem cell, business, medicine.drug
Abstract

Three randomized controlled trials in early severe systemic sclerosis demonstrated that autologous hematopoietic stem cell transplantation was superior to standard cyclophosphamide therapy. This European Society for Blood and Marrow Transplantation multicenter, prospective, non-interventional study was designed to further decipher efficacy and safety of this procedure for severe systemic sclerosis patients in real-life practice and to search for prognostic factors. All consecutive adult patients with systemic sclerosis undergoing a first autologous hematopoietic stem cell transplant between December 2012 and February 2016 were prospectively included in the study. The primary endpoint was progression-free survival. Secondary endpoints were overall survival, non-relapse mortality, response and incidence of progression. Eighty patients with systemic sclerosis were included. The median duration of the follow-up was 24 (range, 6-57) months after stem cell transplantation using cyclophosphamide plus antithymocyte globulin conditioning for all, with CD34+ selection in 35 patients. At 2 years, the progression- free survival rate was 81.8%, the overall survival rate was 90%, the response rate was 88.7% and the incidence of progression was 11.9%. The 100-day non-relapse mortality rate was 6.25% (n=5) with four deaths from cardiac events, including three due to cyclophosphamide toxicity. Modified Rodnan skin score and forced vital capacity improved with time (P24 and older age at transplantation were associated with lower progression-free survival (hazard ratios 3.32 and 1.77, respectively). CD34+-cell selection was associated with better response (hazard ratio 0.46). This study confirms the efficacy of autologous stem cell transplantation, using nonmyeloablative conditioning, in real-life practice for severe systemic sclerosis. Careful cardio-pulmonary assessment to identify organ involvement at the time of the patient’s referral, reduced cyclophosphamide doses and CD34+-cell selection may improve outcomes. The study was registered at ClinicalTrials.gov: NCT02516124.

Published
2021

27. Autoren der Vorauflagen

Author

Abdelhamid, S., primary, Beyer, H.-J., additional, Distler, A., additional, Erdmann, E., additional, Ewe, K., additional, Ferlinz, R., additional, Fischer, J., additional, Fischer, W., additional, Fuchs, E., additional, Gerbershagen, H.-U., additional, Hecking, E., additional, Hertle, F., additional, Höffler, D., additional, Jahnecke, J., additional, Just, H., additional, Kanz, L., additional, Köhler, H., additional, Kremer, G.J., additional, Krück, F., additional, Lemmel, E.-M., additional, Mainzer, K., additional, Mann, K., additional, Meyer zum Büschenfelde, K.-H., additional, Ohler, W., additional, Philipp, M., additional, Philipp, T., additional, Pfannenstiel, P., additional, Preiß, J., additional, Quarz, W., additional, Schuster, H.-P., additional, Schrezenmeir, J., additional, Shah, P.M., additional, Steppling, H., additional, Weihrauch, T.R., additional, Weis, H.J., additional, Wolff, H.P., additional, Wollenweber, J., additional, and Wollschläger, H., additional

Published
2014
Full Text
View/download PDF

29. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

Author

Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

42. Successful double disease control by guselkumab in a patient with Behçet’s disease and psoriasis

Author

Xenitidis, T, Speidel, L, Kanz, L, and Henes, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Behçet’s disease (BD) is a multisystemic inflammatory disorder of unknown aetiology, characterized by recurrent oral aphthosis (OA), genital ulcers (GU), uveitis and cutaneous lesions [ref:1]. Skin involvement regularly consists of papulopustulosis[for full text, please go to the a.m. URL], 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

47. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

Author

Einsele, H, Bamberg, M, Budach, W, Schmidberger, H, Hess, C F, Wörmann, B, Meisner, C, Straka, C, Hebart, H, Trümper, L, Kröger, N, Zander, A R, Hegewisch-Becker, S, Hossfeld, D K, Schmidt, H, Müller, P, Schlimok, G, Hertenstein, B, Peest, D, Metzner, B, Frickhofen, N, Kanz, L, and Bensinger, W I

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results